Consensus estimates ahead of Q1 2024
Alm. Brand Group has published consensus estimates prior to the announcement of the Q1 results.
Consensus estimates are also available via: almbrand.dk
Conference Call
Alm. Brand Group will report its Q1 2024 results on May 2 and host a conference call with management at 11:00 CET on the day of release.
Dial in for analysts and investors (pincode: 978854) :
Denmark: +45 8987 5045
UK: +44 20 3936 2999
USA: +1 646 664 1960
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Mads Thinggaard - Head of IR, Rating & ESG Reporting - mobile no. +45 2025 5469
Press:
Mikkel Lars Nikolajsen - Head of Media Relations - mobile no. +45 2218 5711
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fejl i indre værdi i Investeringsforeningen Sparinvest6.5.2024 11:47:47 CEST | pressemeddelelse
Det skal oplyses, at der den 3. maj i perioden 09:45 til 10:55, er sket en fejl i beregningen af indre værdi for nedenstående afdeling. Indre værdi for nedenstående afdeling har i perioden været undervurderet. OrderbookcodeAfdelingsnavnISINPåvirkningSPIUSGKLSparindex INDEX USA Growth KLDK0010298272-0,68% Eventuel henvendelse vedrørende denne meddelelse kan rettes til NPA.PM@nykredit.dk eller CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze
Prepayments, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | Press release
To Nasdaq Copenhagen A/SExecutive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 6 May 2024 Company Announcement No 34/2024 Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 3 May 2024. Please find the data in the attached file. The information will also be available on www.rd.dk. Yours sincerely The Executive Management Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068. Attachments Nr 34_Ekstraordinaere indfrielser_ukBilag til selskabsmeddelelse nr 34-2024
Ekstraordinære indfrielser, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | pressemeddelelse
Til Nasdaq Copenhagen A/SDirektionen Bernstorffsgade 40 1577 København V www.rd.dk Telefon 7012 5300 6. maj 2024 Selskabsmeddelelse nummer 34/2024 Ekstraordinære indfrielser, Realkredit Danmark A/S I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 3. maj 2024. Oplysningerne fremgår af vedhæftede datafil. Oplysningerne vil desuden kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk. For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside. Med venlig hilsen Direktionen Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68. Vedhæftede filer Nr. 34_Ekstraordinaere indfrielser_dkBilag til selskabsmeddelelse nr 34-2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia6.5.2024 11:00:00 CEST | Press release
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4 It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentia
Orion Corporation: Managers’ transactions – Eija Ronkainen6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Eija Ronkainen Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61636/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR Ori